Investors

Problem

Initial market research indicates that 80% of women would try this product and believe it should be available on the market.

Vaginitis is the most common reason women visit their OB/GYN.
15.5M recurrent sufferers in the U.S. with >3 outbreaks/year
70% users DON'T recommend a common topical, over-the-counter antifungal treatment designed for vaginal yeast infections.

Solution

Cooling down infections is the answer.

Vlisse is the all-natural, drug-free cure for vaginal infections, providing immediate symptom relief unlike current drugs.

Why Invest?

Are you looking to contribute to the development of a medical innovation that will make a lasting impact on how vaginal yeast infections are treated?

Coologics is looking for investors to help

fund the final stages of the clinical trial and go-to-market activities for Vlisse.

Contact Dr. Kimberly Langdon to learn how you can become a part of our team.

Watch our ACOG video to learn how Vlisse works.

Investor Overview

Cooling technology platform treating the three largest markets in OB/GYN
Strong issued patents (Utility & Design)
Prevents any other cooling device entry into the market
Multiple conditions including Bacterial Vaginosis & Preterm Birth
Clinical Trial N=49
- 8 trial sites
- 50% complete
- 93% effective
Two FDA Pre-Submission meetings
- De Novo
- Class II-Low-Moderate risk
All-Natural, First Drug-Free, Non-Chemical
Early exit opportunity – pending clinical trial

Scientific Facts

Get the Details

Microbiology of Yeast Infections

What are the scientific facts behind yeast infections?

Trials in:

Sarasota, Florida
Boynton Beach, Florida

Pivotal Trial (2025-2026)

50% Complete
Results (25% of Data)
- 93% Efficacy
- 8/9 (89%) *CC VVC/Mixed
- 18/22 (82%) CC Unknown Dx
Colombia: 6/6 (100%) CC VVC
FDA criteria for clearance are 50% CC based on the last drug
Zero safety issues
Faster symptom resolution